inosine-pranobex and Herpes-Genitalis

The objective of the study is to evaluate the efficacy and safety of oral inosine pranobex as compared with acyclovir in the treatment of recurrent herpes labialis (RHL) and recurrent herpes genitalis (RHG). A multicenter double-blind, double-dummy, randomized, controlled, parallel group trial was conducted in 144 patients with RHL and 144 RHG. Patients were assigned to treatment in one of two groups: (i) inosine pranobex group (active inosine pranobex, 1 g four times daily, and acyclovir placebo); or (ii) acyclovir group (active acyclovir, 200 mg five times daily, and inosine pranobex placebo). The total symptom score (TSS) of patients with RHL did not differ in the inosine pranobex and acyclovir group on the 3rd or 7th day of treatment. There was also no difference in the efficacy rates between the two groups. No difference of TSS was observed between patients with RHG taking inosine pranobex and acyclovir on days 3 or 5 of the treatment, respectively. The short-term clinical recurrence rate of RHG at 3-month follow-up was much lower in the inosine pranobex group than acyclovir group. The incidence of hyperuricemia was higher in the inosine pranobex group than acyclovir group. In conclusion, inosine pranobex was as effective as acyclovir in treating RHL and RHG with significantly greater reduction of the short-term recurrence rate of herpes genitalis at 3-month follow up. Long-term recurrence rates at 6 months or longer remain to be determined. Hyperuricemia should be monitored during the treatment.

Topics: Acyclovir; Adult; Antiviral Agents; China; Double-Blind Method; Female; Herpes Genitalis; Herpes Labialis; Humans; Inosine Pranobex; Male; Middle Aged; Recurrence

To compare the efficacy and safety of oral acyclovir (400 mg twice daily) with oral isoprinosine (500 mg twice daily) in the suppression of recurrent genital herpes.. Double-blind, double-dummy, randomised, controlled, parallel group trial.. 13 centres in UK, Belgium and Germany.. 127 immunocompetent patients with frequently recurring genital herpes.. Proportions of patients reporting recurrences, recurrence frequency, and mean duration of lesions during breakthrough recurrences in each treatment group during a 6 month treatment period; time to first recurrence during treatment and follow-up after treatment cessation.. During treatment, acyclovir recipients showed significant differences (p < 0.05) when compared with isoprinosine recipients in terms of a lower proportion reporting recurrences (31% vs 96%), a reduced mean number of reported recurrences per patient (0.6 vs 3.6), a shorter mean duration of breakthrough lesions (6.4 days vs 8.2 days), and a longer mean time (standard error) to first recurrence (143.7 (9.1) days vs 40.5 (5.4) days. The mean time to first recurrence after treatment cessation did not differ between the two groups. As compared with placebo recipients, isoprinosine treated patients had an increased recurrence frequency (3.6 vs 2.5) during treatment, and a shorter time to first recurrence after treatment cessation. All treatments were well tolerated without serious adverse events or toxicity.. Acyclovir is very effective in suppressing recurrent genital herpes and is clearly superior to isoprinosine which is not clinically useful in the dosage studied.

Topics: Acyclovir; Administration, Oral; Double-Blind Method; Female; Herpes Genitalis; Humans; Inosine Pranobex; Male; Recurrence; Time Factors

The suppressive action of acyclovir and inosine pranobex was compared in a randomised double blind controlled trial in patients with frequently recurring genital herpes. Fourteen patients received acyclovir and 17 inosine pranobex. Treatment continued for 12 weeks. The time to the first recurrence was significantly longer and the frequency of recurrences significantly less in the recipients of acyclovir. No important side effects were noted. It is concluded that acyclovir is the treatment of choice to suppress often recurring genital herpes.

Topics: Acyclovir; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Herpes Genitalis; Humans; Inosine; Inosine Pranobex; Male; Random Allocation; Recurrence

A total of 77 patients with first-attack genital herpes received acyclovir, 400 mg four times per day, inosine pranobex, 1 g four times per day, or both drugs for seven days. Patients treated with acyclovir healed in a shorter time and had a shorter duration of viral shedding and symptoms than those treated with inosine pranobex. Neither acyclovir nor inosine pranobex had any effect on the time to first occurrence or the frequency of subsequent recurrences. Preliminary results from two trials suggest that suppressive acyclovir is more efficacious than inosine pranobex in patients with frequently recurring genital herpes.

Topics: Acyclovir; Adjuvants, Immunologic; Antiviral Agents; Clinical Trials as Topic; Female; Herpes Genitalis; Humans; Inosine; Inosine Pranobex; Male; Random Allocation; Recurrence

77 patients with a first attack of genital herpes were entered into a double-blind trial to compare the efficacy of acyclovir with that of inosine pranobex. 24 patients received acyclovir with that of inosine pranobex, and 28 both drugs. Patients treated with acyclovir or both drugs healed more quickly and had a shorter duration of viral shedding than those treated with inosine pranobex. The time to first recurrence and frequency of subsequent recurrences were similar in the three treatment groups. Acyclovir is the treatment of choice for patients with a first attack of genital herpes.

Topics: Acyclovir; Adult; Clinical Trials as Topic; Double-Blind Method; Female; Herpes Genitalis; Humans; Inosine; Inosine Pranobex; Male; Random Allocation; Recurrence; Simplexvirus; Time Factors

Topics: Clinical Trials as Topic; Female; Herpes Genitalis; Humans; Inosine; Inosine Pranobex; Male; Stomatitis, Herpetic

Topics: Clinical Trials as Topic; Double-Blind Method; Female; Herpes Genitalis; Herpes Labialis; Herpes Simplex; Humans; Inosine; Inosine Pranobex; Male; Recurrence

Topics: Female; Herpes Genitalis; Herpes Labialis; Humans; Inosine; Inosine Pranobex; Male

Topics: Female; Herpes Genitalis; Humans; Inosine; Inosine Pranobex; Male

The reason for giving substances with immunostimulatory properties is to restore or normalize immune functions. Since various human pathogenic viruses can induce immunodepression, the administration of immunostimulants offers a possibility for therapeutic intervention in the immune system. This could be demonstrated. Various virus infections can effectively be influenced by the synthetic immunostimulating agent Inosine Pranobex.

Topics: Antibody Formation; Encephalitis; Female; Herpes Genitalis; Herpes Labialis; Herpes Zoster; Humans; Immunity, Cellular; Immunologic Deficiency Syndromes; Inosine; Inosine Pranobex; Male; Subacute Sclerosing Panencephalitis; Virus Diseases